James H. Wong

Vancouver, BC, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Exploring The Role of GLP-1 Receptor Agonists and DPP4 Inhibitors in the Treatment of Opioid Use Disorder: A Scoping Review.

Exploring The Role of GLP-1 Receptor Agonists and DPP4 Inhibitors in the Treatment of Opioid Use Disorder: A Scoping Review.

Journal: Journal of dual diagnosis

Published: August 24, 2026

Utilizing Apple Vision Pro for Mindfulness Intervention to Reduce Pain and Anxiety in a Hospitalized Patient With Mixed Connective Tissue Disease: A Case Report.

Utilizing Apple Vision Pro for Mindfulness Intervention to Reduce Pain and Anxiety in a Hospitalized Patient With Mixed Connective Tissue Disease: A Case Report.

Journal: Cureus

Published: April 24, 2026

Naloxone dosing: An evolving unregulated drug landscape, care setting considerations, and the need for research.

Naloxone dosing: An evolving unregulated drug landscape, care setting considerations, and the need for research.

Journal: Addiction (Abingdon, England)

Published: June 25, 2025

24-48 h initiation by transdermal buprenorphine for the treatment of opioid use disorder in the inpatient setting: a retrospective chart review.

24-48 h initiation by transdermal buprenorphine for the treatment of opioid use disorder in the inpatient setting: a retrospective chart review.

Journal: Addiction science & clinical practice

Published: May 29, 2025

The Buprenorphine Paradox: How Buprenorphine Triggers and Resolves Opioid Withdrawal.

The Buprenorphine Paradox: How Buprenorphine Triggers and Resolves Opioid Withdrawal.

Journal: Addiction biology

Published: May 03, 2025

Direct Induction of Buprenorphine Extended-Release: A Case Report.

Direct Induction of Buprenorphine Extended-Release: A Case Report.

Journal: Journal of addiction medicine

Published: January 09, 2025

24-Hour Induction of Transdermal Buprenorphine to Buprenorphine Extended-Release.

24-Hour Induction of Transdermal Buprenorphine to Buprenorphine Extended-Release.

Journal: Journal of psychoactive drugs

Published: November 19, 2024

Transition to Extended-release Buprenorphine Injectable Within Seven Days for Opioid Use Disorder Treatment: A Scoping Narrative.

Transition to Extended-release Buprenorphine Injectable Within Seven Days for Opioid Use Disorder Treatment: A Scoping Narrative.

Journal: Journal of addiction medicine

Published: November 06, 2024

Case series: Symptom-inhibited fentanyl induction (SIFI) onto treatment-dose opioid agonist therapy in a community setting.

Case series: Symptom-inhibited fentanyl induction (SIFI) onto treatment-dose opioid agonist therapy in a community setting.

Journal: The American journal on addictions

Published: October 29, 2024

Rapid intravenous symptom-inhibiting fentanyl induction (SIFI) to optimize rotation onto oral opioid agonist therapy among individuals who use unregulated fentanyl: protocol for an open-label, single arm clinical trial.

Rapid intravenous symptom-inhibiting fentanyl induction (SIFI) to optimize rotation onto oral opioid agonist therapy among individuals who use unregulated fentanyl: protocol for an open-label, single arm clinical trial.

Journal: Addiction science & clinical practice

Published: October 07, 2024

Patient-elected low-dose intravenous naloxone for rapid buprenorphine induction: a case report.

Patient-elected low-dose intravenous naloxone for rapid buprenorphine induction: a case report.

Journal: Addiction science & clinical practice

Published: October 03, 2024

Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder.

Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder.

Journal: Addiction science & clinical practice

Published: January 15, 2024

Showing 1-12 of 28

Last Updated: 09/26/2026